DXCM Stock Analysis — Dexcom
Sector: Healthcare
AI Verdict
Dexcom trades at 22.6x next year's earnings with 16.1% EPS growth expected, so you're paying a fair price if its sensor and data moat keeps rivals at bay, but the market is no longer giving it a premium for execution.
Competitive Moat
Dexcom dominates continuous glucose monitoring (CGM) for diabetes with proprietary sensor technology and deep integration into digital health platforms. Its moat comes from FDA-cleared algorithms, sticky relationships with endocrinologists, and a massive real-world data advantage that competitors struggle to match.
Summary
Dexcom's forward P/E of 22.6x with 16.1% expected EPS growth puts it right at the intersection of medtech innovation and value debate.
Where It Stands
Shares are down -27.33% over the past year, RSI sits at 45.3 (cooling but not oversold), and the stock trades at 22.6x forward earnings versus a healthcare sector median of 22x.
Key Metrics
- RSI: 45.3 — Neutral
- Trailing P/E: 26.3x
- Forward P/E: 22.6x
- PEG Ratio: 1.59
- Earnings Growth: +0.2%
- Revenue Growth: +0.2%
- Market Cap: $23.5B
- 1-Year Return: -27.33%
- 52-Week High: $89.98
- 52-Week Low: $54.11
Analyst Consensus
32 Buy · 4 Hold · 1 Sell (37 analysts)
Bull Case
A 16.1% forward EPS growth rate at 22.6x forward P/E means you're paying a fair multiple for double-digit earnings expansion if Dexcom's CGM moat holds.
Bear Case
If the P/E compresses to the sector median of 22x, that's only a 3% downside from here, but the -27.33% 1-year return shows sentiment is fragile if growth stumbles.
Catalyst to Watch
Watch for FDA approvals or new CGM product launches—any sign of competitive encroachment or regulatory delays could shift the growth narrative.